Jens Stahlschmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jens Stahlschmidt has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Marta Cecilia Cohen
School of Medicine and Population Health, Sheffield Teaching Hospital (SYPB), University of Sheffield, Sheffield, UK
2 shared publications - Miguel Reyes-Múgica
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, 1611 NW 12th Avenue, Holtz Center, Room 2147, Miami, FL, 33125, USA.
2 shared publications - Ronald R. de Krijger
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications - Allison F. O'NEill
Department of Pediatric Oncology Dana‐Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School Boston Massachusetts USA
1 shared publication - Antonio R. Perez-Atayde
Department of Pathology Boston Children's Hospital Boston Massachusetts USA
1 shared publication - Christian Vokuhl
Department of Pathology, Division of Paidopathology, University Hospital Bonn University of Bonn Bonn Germany
1 shared publication
Latest Publications
- Open Access
- 20 August 2025
- Published by Wiley in Histopathology
- Vol. 87 (6) , 802-814
Pathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting
Aims: Hepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus‐based dataset for the pathology reporting of hepatoblastoma resection specimens. The dataset was developed under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of international pathology and cancer organizations. Methods and results: According to the ICCR's guidelines for dataset development, an international expert panel including paediatric pathologists and a paediatric oncologist specialized in liver tumours developed a set of core and non‐core data items for hepatoblastoma resection specimens based on critical review and discussion of current evidence available. Members of the panel were specialists working in tertiary paediatric hospitals, central reviewers for international paediatric liver tumours consortia and/or involved in paediatric liver tumour trials expert committees. Commentaries were provided to support each data item, explaining the rationale for selecting them as a ‘core’ or ‘non‐core’ elements, their clinical relevance and highlighting potential areas of lack of evidence, including clinical, macroscopic, microscopic and ancillary testing considerations. The hepatoblastoma dataset was finalized and ratified following international public consultation and is published on the ICCR website for wide implementation. Conclusion: This is the first international dataset developed by an international expert panel for reporting hepatoblastoma resection specimens aimed to promote high‐quality, standardized pathology reporting of these rare paediatric liver tumours. The adoption and implementation of this hepatoblastoma data set, freely available worldwide on the ICCR website ( www.iccr‐cancer.org/data‐sets ), will facilitate accurate reporting and enhance the consistency of data collection, support retrospective and inform prospective research and ultimately help to improve clinical outcomes of children with hepatoblastoma.
- 20 August 2025
- Published by Wiley in Histopathology
- Vol. 87 (6) , 802-814
Open AccessPathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting
Aims: Hepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus‐based dataset for the pathology reporting of hepatoblastoma resection specimens. The dataset was developed under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of international pathology and cancer organizations. Methods and results: According to the ICCR's guidelines for dataset development, an international expert panel including paediatric pathologists and a paediatric oncologist specialized in liver tumours developed a set of core and non‐core data items for hepatoblastoma resection specimens based on critical review and discussion of current evidence available. Members of the panel were specialists working in tertiary paediatric hospitals, central reviewers for international paediatric liver tumours consortia and/or involved in paediatric liver tumour trials expert committees. Commentaries were provided to support each data item, explaining the rationale for selecting them as a ‘core’ or ‘non‐core’ elements, their clinical relevance and highlighting potential areas of lack of evidence, including clinical, macroscopic, microscopic and ancillary testing considerations. The hepatoblastoma dataset was finalized and ratified following international public consultation and is published on the ICCR website for wide implementation. Conclusion: This is the first international dataset developed by an international expert panel for reporting hepatoblastoma resection specimens aimed to promote high‐quality, standardized pathology reporting of these rare paediatric liver tumours. The adoption and implementation of this hepatoblastoma data set, freely available worldwide on the ICCR website ( www.iccr‐cancer.org/data‐sets ), will facilitate accurate reporting and enhance the consistency of data collection, support retrospective and inform prospective research and ultimately help to improve clinical outcomes of children with hepatoblastoma.
- 24 February 2025
- Published by Wiley in Histopathology
- Vol. 87 (3) , 343-356
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR)
Peripheral neuroblastic tumours are the most common extracranial solid neoplasms occurring in children. Proper classification is critical for directing therapy and predicting prognosis. Nonetheless, their relative rarity makes accurate pathological assessment challenging, even for experienced pathologists. Here we report on a new international data set for the pathology reporting of biopsy and resection specimens with peripheral neuroblastic tumours. The data set was produced under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter‐)national pathology and cancer organisations. According to the ICCR's process for data set development, an international expert panel consisting of paediatric pathologists and oncologists produced a set of core and non‐core data items for biopsy and resection specimens based on a critical review and discussion of current evidence. All professionals involved were neuroblastic tumour experts affiliated with tertiary referral centres. Commentary was provided for each data item to explain the rationale for selecting it as a core or non‐core element, its clinical relevance and to highlight potential areas of disagreement or lack of evidence, in which case a consensus position was formulated. Following international public consultation, the documents were finalised and ratified, and the data sets, including a synoptic reporting guide, were published on the ICCR website. This first international data set for paediatric peripheral neuroblastic tumours is intended to promote high‐quality, standardised pathology reporting. Its widespread adoption will improve the consistency of reporting, facilitate multidisciplinary communication and enhance comparability of data, all of which will help to improve management of children with peripheral neuroblastic tumours.
- 24 February 2025
- Published by Wiley in Histopathology
- Vol. 87 (3) , 343-356
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR)
Peripheral neuroblastic tumours are the most common extracranial solid neoplasms occurring in children. Proper classification is critical for directing therapy and predicting prognosis. Nonetheless, their relative rarity makes accurate pathological assessment challenging, even for experienced pathologists. Here we report on a new international data set for the pathology reporting of biopsy and resection specimens with peripheral neuroblastic tumours. The data set was produced under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter‐)national pathology and cancer organisations. According to the ICCR's process for data set development, an international expert panel consisting of paediatric pathologists and oncologists produced a set of core and non‐core data items for biopsy and resection specimens based on a critical review and discussion of current evidence. All professionals involved were neuroblastic tumour experts affiliated with tertiary referral centres. Commentary was provided for each data item to explain the rationale for selecting it as a core or non‐core element, its clinical relevance and to highlight potential areas of disagreement or lack of evidence, in which case a consensus position was formulated. Following international public consultation, the documents were finalised and ratified, and the data sets, including a synoptic reporting guide, were published on the ICCR website. This first international data set for paediatric peripheral neuroblastic tumours is intended to promote high‐quality, standardised pathology reporting. Its widespread adoption will improve the consistency of reporting, facilitate multidisciplinary communication and enhance comparability of data, all of which will help to improve management of children with peripheral neuroblastic tumours.
- Open Access
- 28 March 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 192 (6) , 943-955
Barrier-Forming Potential of Epithelial Cells from the Exstrophic Bladder
- 28 March 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 192 (6) , 943-955
Open AccessBarrier-Forming Potential of Epithelial Cells from the Exstrophic Bladder
- 10 December 2021
- Published by Springer Nature in Der Pathologe
- Vol. 42 (S2) , 170-174
Histologische Aspekte des akuten Leberversagens bei Kindern
Zusammenfassung Das pädiatrische akute Leberversagen (pALV) repräsentiert die Endstufe verschiedenster pathologischer Ätiologien, die innerhalb von Tagen bis Wochen zu einer lebensbedrohlichen Multisystemerkrankung mit oder ohne hepatischer Enzephalopathie führen können. Die Ätiologie des pALV ist weit gefächert und nicht nur abhängig vom Alter des Kindes, sondern auch der geografischen Herkunft. Generell sind die Non-A–E-Hepatitiden/seronegativen Hepatitiden am häufigsten vertreten. Ein Großteil des neonatalen ALV beruht auf einer fetalen alloimmunen Lebernekrose (GALD), gefolgt von metabolischen und infektiösen Ursachen bei Säuglingen. Bei älteren Kindern sind Virushepatitiden und medikamentöse/toxische Ursachen häufig. Im Teenageralter sind vor allem der Morbus Wilson und autoimmune Ätiologien zu finden. Andere Ursachen sind Infektionen, Ischämien und maligne (onkohämatologische) Erkrankungen. Bei der Pathogenese spielt die hepatozelluläre Nekrose, die die Rate der Hepatozytenregeneration übersteigt, eine zentrale Rolle. Differenzialdiagnostisch sollte eine bereits bestehende chronische Lebererkrankung immer vorweg ausgeschlossen werden. Die „Pediatric Acute Liver Failure (PALF) Study Group“ (NIH) entwickelte diesbezüglich einen klinische Kriterienkatalog für den angloamerikanischen Raum. Bei der pathomorphologischen Diagnose ist die Möglichkeit, dass die Biopsie nicht repräsentativ ist, immer mit zu berücksichtigen. Durch die nichtspezifische Nekrose kann die Aussagekraft der Leberbiopsie im pALV begrenzt sein. Die histologische Diagnose stellt in jedem Fall nur einen Baustein bei der Diagnosefindung dar. In den meisten Fällen (mit bestehender Koagulopathie) ist eine Leberbiopsie sogar kontraindiziert.
- 10 December 2021
- Published by Springer Nature in Der Pathologe
- Vol. 42 (S2) , 170-174
Histologische Aspekte des akuten Leberversagens bei Kindern
Zusammenfassung Das pädiatrische akute Leberversagen (pALV) repräsentiert die Endstufe verschiedenster pathologischer Ätiologien, die innerhalb von Tagen bis Wochen zu einer lebensbedrohlichen Multisystemerkrankung mit oder ohne hepatischer Enzephalopathie führen können. Die Ätiologie des pALV ist weit gefächert und nicht nur abhängig vom Alter des Kindes, sondern auch der geografischen Herkunft. Generell sind die Non-A–E-Hepatitiden/seronegativen Hepatitiden am häufigsten vertreten. Ein Großteil des neonatalen ALV beruht auf einer fetalen alloimmunen Lebernekrose (GALD), gefolgt von metabolischen und infektiösen Ursachen bei Säuglingen. Bei älteren Kindern sind Virushepatitiden und medikamentöse/toxische Ursachen häufig. Im Teenageralter sind vor allem der Morbus Wilson und autoimmune Ätiologien zu finden. Andere Ursachen sind Infektionen, Ischämien und maligne (onkohämatologische) Erkrankungen. Bei der Pathogenese spielt die hepatozelluläre Nekrose, die die Rate der Hepatozytenregeneration übersteigt, eine zentrale Rolle. Differenzialdiagnostisch sollte eine bereits bestehende chronische Lebererkrankung immer vorweg ausgeschlossen werden. Die „Pediatric Acute Liver Failure (PALF) Study Group“ (NIH) entwickelte diesbezüglich einen klinische Kriterienkatalog für den angloamerikanischen Raum. Bei der pathomorphologischen Diagnose ist die Möglichkeit, dass die Biopsie nicht repräsentativ ist, immer mit zu berücksichtigen. Durch die nichtspezifische Nekrose kann die Aussagekraft der Leberbiopsie im pALV begrenzt sein. Die histologische Diagnose stellt in jedem Fall nur einen Baustein bei der Diagnosefindung dar. In den meisten Fällen (mit bestehender Koagulopathie) ist eine Leberbiopsie sogar kontraindiziert.